ACP
GBIO

Acuta Capital Partners’s Generation Bio GBIO Stock Holding History

Acuta Capital Partners’s Portfolio GBIO Stock Details GBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-10,000
Closed -$2.1M – 51
2020
Q2 		$2.1M Buy
+10,000
New +$2.23M 0.61% 41

Other funds holding GBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return

Acuta Capital Partners's GBIO Position: Q3 2020 in Review

Acuta Capital Partners sold out of Generation Bio (GBIO) in Q3 2020, closing a stake of 10,000 shares — an estimated $2.1M sold.

Acuta Capital Partners first reported a position in GBIO in Q2 2020 and held it in 1 quarter. The position peaked at $2.1M in Q2 2020. 53 funds tracked by Wall St. Rank hold GBIO as of Q3 2020.

  • Acuta Capital Partners reported no remaining Generation Bio position as of Q3 2020 after selling out during the quarter.
  • Acuta Capital Partners sold 10,000 Generation Bio shares in Q3 2020, an estimated $2.1M.
  • Acuta Capital Partners first reported a position in Generation Bio in Q2 2020 and held it in 1 quarter.
  • Acuta Capital Partners's Generation Bio position peaked at $2.1M in Q2 2020.
  • 53 funds tracked by Wall St. Rank held Generation Bio as of Q3 2020.

Based on Acuta Capital Partners's 13F filing for Q3 2020, filed 16 Nov 2020.